Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Ryan T Hurt,1–4 Manpreet S Mundi,3 Jon O Ebbert5 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 3Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, M...
Enregistré dans:
Auteurs principaux: | Hurt RT, Mundi MS, Ebbert JO |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/30bc9e7e93e84bcfac4840001f22ecfc |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
par: Gong M, et autres
Publié: (2020) -
Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
par: Muhan Jing, et autres
Publié: (2021) -
Lorcaserin for weight management
par: Taylor JR, et autres
Publié: (2013) -
Off-label drugs for weight management
par: Hendricks EJ
Publié: (2017) -
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
par: Sweeting AN, et autres
Publié: (2014)